Fig. 4.

Neuropathological characterization of RML-infected mice treated with aryl amides. Representative sections shown from the sensory cortex and hippocampus of WT (A) and Tg4053 (B) mice treated with aryl amides. Double immunolabeling (upper panels) against PrP (green) and GFAP (red) and H&E staining (lower panels) show that the characteristic neuropathology of prion diseases remains upon treatment. (C) PrP immunoreactivity in the hippocampus and surrounding cortex from a mouse treated with compound 14 shows intensity in the corpus callosum (white arrows), which is not observed in the vehicle-treated control. Scale bars for the sensory cortex and hippocampus represent 25 and 50 µM, respectively, and apply to all panels for those regions.